Premium
Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor‐associated antigens
Author(s) -
Shi FuDong,
Zhang JianYing,
Liu Daorong,
Rearden Ann,
Elliot Max,
Nachtsheim Dan,
Daniels Tracy,
Casiano Carlos A.,
Heeb Mary Jo,
Chan Edward K.L.,
Tan Eng M.
Publication year - 2005
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20181
Subject(s) - prostate cancer , antigen , cancer , autoantibody , antibody , immunoscreening , immune system , medicine , prostate , prostate specific antigen , immunology , pca3 , biology , complementary dna , cdna library , biochemistry , gene
BACKGROUND Cytoplasmic p90 autoantigen was recently cloned from a cDNA expression library using serum antibody from a cancer patient. The humoral immune response to p90 in prostate cancer and benign prostatic hyperplasia (BPH) was examined. METHODS An antigenic fragment of recombinant p90 protein and several other tumor‐associated antigens (TAAs) were used in ELISA and Western blotting to detect antibodies in sera from patients with prostate cancer, BPH, and other controls. RESULTS Autoantibodies to p90 were detected in 30.8% of 133 prostate cancer patients versus 1.5% in 68 BPH patients. When a selected panel of six TAAs including p90 were used for immunoscreening, the cumulative positive reactions in prostate cancer sera reached 92.5%, significantly higher than in BPH and other control sera. Antibodies to p90 showed the highest frequency in prostate cancer (30.8%), followed by antibodies to p62 (22.6%). CONCLUSIONS A panel of six selected TAAs was shown to have high sensitivity and specificity as immunodiagnostic markers in prostate cancer. © 2004 Wiley‐Liss, Inc.